Tempus, Groupon Co-Founder's Medical Technically Startup, Is Exploring an IPO
(Bloomberg) -- Tempus Labs Inc., a precision medicine startup led by a Groupon Inc. co-founder, is exploring a U.S. initial public offering, according to people with knowledge of the matter.
The Chicago-based company is considering a stock-market debut as soon as the first half of 2022, the people said, asking not to be identified discussing information that isn't public. Plans could change and timing could shift, one of the people said.
Tempus spokeswoman Erin Carron declined to comment.
The company said in December 2020 that it was valued at $8.1 billion after raising $200 million in equity financing and $250 million in convertible debt. Investors included Baillie Gifford, Google, Franklin Templeton, Novo Holdings and funds managed by T. Rowe Price Group Inc., Tempus said at the time. Earlier investors include Steve Case's Revolution Growth and NEA.
Founded in 2015, Tempus says it's built the world's largest library of clinical and molecular data, which is used to inform patient care. The company is working with Cedars-Sinai Cancer on an initiative to develop personalized treatment using virtual replicas of patients' DNA, RNA and protein. Separately, Tempus has announced adding a collection of predictive algorithm laboratory-developed tests.
“We are very much aware of our responsibility and the power of this moment in time, one in which we now possess the technological capability to use artificial intelligence to eradicate disease and help people live longer and healthier lives,” Tempus Chief Executive Officer Eric Lefkofsky said in the December statement. Lefkofsky, a billionaire, co-founded Groupon, advertising-services company Mediaocean and venture-capital firm Lightbank.
In February, Tempus added Nobel laureate Jennifer Doudna to its board and, in July, the company announced it had bulked up its leadership team, including the promotion of Jim Rogers to the role of chief financial officer.
Tempus competes in part with PathAI, a startup seeking to advance pathology with artificial intelligence that counts D1 Capital Partners, General Atlantic and Tiger Global Management among its backers.
Read more: Goldman-Backed InferVision Said to Pick Banks for Hong Kong IPO
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.